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INTRODUCTION
Pseudomonas aeruginosa is an important nosocomial pathogen
with its ability to propagate on medical devices, hospital
environment and even in disinfectants. It causes high mor-
bidity and mortality in the services of oncology, hematolo-
gy, surgery, burn and intensive care units (1). Infections due
to this virulent organism are difficult to both control and
treat because of intrinsic resistance to many antimicrobial
agents (2, 3).
Imipenem, a broad-spectrum β -lactam antibiotic, is one
of the most effective drug against P. aeruginosa. The incidence
of imipenem-resistance is increasing among gram negative
bacilli, particularly P. aeruginosa, often associated with resis-
tance to other antipseudomonal drugs (4). The increasing
resistance of P. aeruginosa is a growing threat to the clinical
management of such infections (5-7). 
P. aeruginosa infections are frequently encountered in Turk-
ish hospitals with resistance to the antimicrobial agents com-
monly used against such bacterial infections (8). In this study,
we investigated the risk factors for nosocomial infections of
imipenem-resistant P. aeruginosa (IRPA).
MATERIALS AND METHODS
The hospital setting and study population
A prospective case-control study was conducted at Ankara
Numune Education and Research Hospital (ANERH) in
Turkey. ANERH is an 1,100-bed referral and tertiary-care
hospital. The hospital contains all major services except pedi-
atric department, including medical and surgical sub-spe-
cialties, medical and surgical intensive care units (ICUs).
The annual number of discharges was 55,422 in 2004. 
Antibiotic policy
An antibiotic restriction policy has been carrying out in
ANERH since January 1999. The restriction is on the orders
of certain antibiotics; prior consultation with an infection
disease (ID) specialist is required for ceftazidime, cefepime,
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Imipenem-Resistant Pseudomonas aeruginosa: Risk Factors for 
Nosocomial Infections
The aim of this study was to determine the risk factors for nosocomial infections of
imipenem-resistant Pseudomonas aeruginosa (IRPA). A prospective case-control
study was performed at a tertiary care hospital in Ankara from January to Decem-
ber 2004. The patients with nosocomial P. aeruginosa infection were included in
the study. The features of the patients with IRPA infections were compared to those
with imipenem-sensitive P. aeruginosa (ISPA) infections. Only the first isolation of
P. aeruginosa was considered. Nosocomial infections were defined according to
Center for Disease Control (CDC) criteria. IRPA was isolated from 75 (44.1%)
patients, and ISPA was isolated from 95 (55.9%) patients during the study period.
IRPA were most frequently isolated from endotracheal aspirate (19%) cultures (p=
0.048), whereas ISPA were most frequently isolated from urine (28%) cultures (p=
0.023). In multivariate analysis, a longer duration of hospital stay until P. aeruginosa
isolation (odds ratio [OR], 1.027; 95% confidence interval [CI], 1.002-1.054, p=0.034),
arterial catheter administration (OR, 2.508; 95% CI, 1.062-5.920, p=0.036), van-
comycin (OR, 2.882; 95% CI, 1.130-7.349, p=0.027), piperacillin-tazobactam (OR,
6.425; 95% CI, 2.187-18.875, p=0.001), and imipenem (OR, 3.580; 95% CI, 1.252-
10.245, p=0.017) treatment within the 14 days before isolation of IRPA were inde-
pendently associated with imipenem resistance. It was concluded that treatment
with imipenem, vancomycin and piperacillin-tazobactam were major risk factors for
IRPA infections in hospitalized patients. The nosocomial occurrence of IRPA was
also strongly related to the duration of hospital stay, arterial catheter administration.
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imipenem, meronem, ticarcilin-clavulanate, piperacillin-
tazobactam, cephaperazon-sulbactam, intravenous quinolones,
intravenous aminoglycosides, linezolid, vancomycin, and
teicoplanin.
Case definition and collection of data
A prospective surveillance was conducted. All patients,
who had nosocomial P. aeruginosa infection at any site, were
included in the study from January to December 2004.
Patients were excluded from the study if P. aeruginosa had
been isolated within 48 hr of admission and younger than
16 yr of age.
Only the first P. aeruginosa isolate from each patient was
evaluated. The clinical significance (colonization or infec-
tion) of each P. aeruginosa isolate and the type of infection
were assessed according to the Center for Disease Control
(CDC) criteria by infectious disease specialists (9). Urinary
tract infection in a patient with an indwelling bladder catheter
was diagnosed with detection of pyuria (≥10 leukocytes/
μ L), growth of ≥105 CFU/mL bacteria (no more than two
species) in urine culture and clinical signs of infection (fever
≥38℃, leukocytosis, abnormal macroscopic appearance of
urine, presence of urinary nitrite). In patients assisted by me-
chanical ventilation, pneumonia was defined when a new or
progressive infiltrate or consolidation in chest radiography
in the presence of purulent tracheal secretions, supported by
a growth of ≥105 CFU/mL bacteria in a quantitative cul-
ture of deep endotracheal aspirate. For non-ventilated pati-
ents, the diagnosis of nosocomial pneumonia was considered
when they had a compatible chest radiography and purulent
sputum, with Gram’s stain and sputum culture document-
ing the presence of a pathogen microorganism. Surgical site
infection was defined as the presence of purulent drainage,
and positive clinical findings (pain, tenderness, localized
swelling, redness or heat at the site of incision, spontaneous-
ly opening of the incision) supported by the microbiologic
analysis of specimens. Sepsis was diagnosed by presence of
sepsis criteria and positive blood cultures. Patients colonized
with P. aeruginosa were excluded.
Data were extracted to individual forms for each patient.
The form included age, sex, diagnosis, date of admission to
hospital or ICU, hospitalization before ICU, length of hos-
pital and ICU stay, transfer from another hospital, comorbidity
(renal failure, hepatic failure, malignancy, immunosupres-
sion, diabetes mellitus, chronic lung disease, malnutrition,
or transplantation), elective or emergent surgical operation,
Acute Physiological and Chronic Health Evaluation (AP-
ACHE II) score, ventilator support, physical examination
findings, haematological and biochemical test results, antibi-
otics given to the patient, culture and antimicrobial suscep-
tibility test results, time interval between hospital admis-
sion and isolation of the first positive P. aeruginosa culture.
Exposures to antimicrobial drugs were also explored. Prior
antibiotic use was defined as at least 24 hr of therapy during
the 14 days prior to isolation of the P. aeruginosa.
The patients were defined as IRPA cases (case patients) if
they had IR P. aeruginosa infections and as imipenem-sensi-
tive P. aeruginosa (ISPA) cases (control patients) if they had IS
P. aeruginosa infections. 
Microbiological examination
All P. aeruginosa were isolated prospectively in the micro-
biology laboratory of ANERH. Identification and antimicro-
bial susceptibility of the isolated strains were done by VITEK
automated system (BioMerieux, Marcy I’Etoile, France).
GNI+ panel was used for the identification and GN 528
panel for the detection of antimicrobial susceptibility. The
isolates with minimum inhibitory concentration (MIC) value
≥8 μ g/mL were recorded as IR and MIC value <8 μ g/mL as
IS. The following antibiotics were tested: amikacin, gentam-
icin, aztreonam, ceftazidime, cefepim, imipenem, netilmicin,
ciprofloxacin, pefloxacin, piperacillin, piperacillin-tazobac-
tam, ticarcillin, ticarcillin clavulanate, and trimethoprim-
sulphamethoxazole. 
Statistical analysis
Statistics were run with STATA 7.0 software package (Col-
lege station, TX, U.S.A.).
Potential risk factors were analyzed by univariate and mul-
tivariate analysis. Results are expressed as mean±SD if not
indicated otherwise. Student’s t-test for independent and
paired continuous variables and chi-square test or Fisher’s
exact test was used when appropriate to compare proportions.
Variables with a p value of <0.05 in the univariate analysis
were entered in a logistic regression model with backward
selection of independent variables for multivariate analysis.
A p value of <0.05 was considered significant. 
RESULTS
During the study period, P. aeruginosa infections were
detected in 170 patients. The mean age was 48.0±20.3
and 117 (69%) were male. The mean age was 49.7±19.9
for ISPA and 45.9±20.3 for IRPA patients. Sixty-three
(66.3%) of ISPA patients were male and 54 (72%) of IRPA
patients were male. ICU patients accounted for 58 (34%) of
the infected patients. Sixty-six percent of all patients were in
clinical wards. The most frequent infection was surgical site
infection (SSI) (57%), followed by urinary tract infection
(22%), pneumonia (13%) and blood stream infection (8%)
(Table 1).
Of the 170 patients, 75 (44.1%) had IRPA and 95 (55.9
%) had ISPA infections. The frequency of IRPA infections
was 1.35 cases/1,000 hospital admissions. In 29 (39%) of984 P. Onguru, A. Erbay, H. Bodur, et al.
IRPA patients, underlying diseases were present (13 [17%]
hypertension, 10 [13%] diabetes mellitus, 9 [12%] malig-
nancy, 6 [8%] immunosuppression, 7 [9%] chronic obstruc-
tive lung disease, 5 [7%] steroid use, 2 [3%] dialysis, 2 [3%]
chemotherapy, 4 [5%]coronary artery disease, 5 [7%]conges-
tive heart disease). In 53 (56%) of ISPA patients, comorbi-
dies were detected (24 [25%] hypertension, 22 [23%] dia-
betes mellitus, 17 [18%] malignancy, 13 [14%] immuno-
suppression, 8 [8%] chronic obstructive lung disease, 7 [7%]
steroid use, 9 [10%] dialysis, 7 [7%] chemotherapy, 4 [4%]
coronary artery disease, 3 [3%] congestive heart disease, 1
[1%] hepatic failure, 1 [1%] chronic alcohol consumption,
and 1 [1%] splenectomy). IRPA cases had more frequently
pneumonia (19% vs. 7%, p=0.048), whereas ISPA cases had
more frequently urinary tract infection (28% vs. 15%, p=
0.023).
The mean duration of hospital stay until P. aeruginosa iso-
lation was 22.01±16.6 days in IRPA infections, whereas
14.06±12.7 days in ISPA infections (p<0.001). Forty-one
percent of the patients with IRPA infection and 28% of the
patients with ISPA infection were followed at ICU.
In ICUs IRPA infections were seen more frequently than
wards (53% and 39%, respectively, p=0.078). The services
from which patients with IRPA and ISPA infections were
receiving care included medical wards (9% and 37%, respec-
tively) and surgical wards (91% and 63%, respectively, p<
0.001).
Results of the univariate analysis of risk factors for IRPA
are outlined in Table 2. According to the univariate analy-
sis, stay in surgical service (p=0.001), stay in burn unit (p<
0.001), transfer from other services (another clinical service,
another intensive care unit, another hospital) (p=0.034),
longer duration of hospital stay until infection (p<0.001),
tracheostomy (p=0.021), arterial line (p=0.012), mean APA-
CHE-II score (p=0.026), APACHE-II score ≥20 (p=0.042)
and previous use of amikacin (p=0.025), vancomycin (p=
0.001), piperacillin-tazobactam (p=0.007), and imipenem
(p=0.002) were significant risk factors for IRPA infections.
In a logistic regression model, a longer duration of hospital
stay until P. aeruginosa isolation (odds ratio [OR], 1.027; 95%
confidence interval [CI], 1.002-1.054, p=0.034), arterial
catheter administration (OR, 2.508; 95% CI, 1.062-5.920,
p=0.036), vancomycin (OR, 2.882; 95% CI, 1.130-7.349,
p=0.027), piperacillin-tazobactam (OR, 6.425; 95% CI,
Infection
ISPA
n (%)
IRPA
n (%)
Total
n (%)
p
Surgical site infection 54 (58) 43 (57) 97 (57) 0.658
Blood stream infection 7 (7) 7 (9) 14 (8) 0.988
Pneumonia 7 (7) 14 (19) 21 (12) 0.023
Urinary tract infection 27 (28) 11 (15) 38 (22) 0.048
Total 95 (100) 75 (100) 170 (100)
Table 1. Nosocomial infection sites caused by imipenem-sen-
sitive P. aeruginosa (ISPA) and imipenem-resistant P. aerugi-
nosa (IRPA)
Risk factors
IRPA (n=75)
n (%)
ISPA (n=95)
n (%)
p
value
Table 2. Comparison of risk factors for imipenem-resistant P.
aeruginosa (IRPA) infections
Independent risk factors
Odds 
ratio
95% Confidence
interval (CI)
p
Hospital stay until infection 1.027 1.002-1.054 0.034
Arterial line 2.508 1.062- 5.920 0.036
Previous use of imipenem 3.580 1.252-10.245 0.017
Previous use of piperacillin- 6.425 2.187-18.875 0.001
tazobactam
Previous use of vancomycin 2.882 1.130-7.349 0.027
Previous use of combination of  10.909 1.332-89.351 0.0001
vancomycin and imipenem
Table 3. Multivariate analysis (logistic regression) of risk factors
for imipenem-resistant P. aeruginosa (IRPA) infections
Age (mean) 45.9±20.3 49.7±19.9 0.883
Male sex  54 (72) 63 (66.3) 0.427
ICU stay 31 (41) 27 (28) 0.078
Comorbidity 29 (39) 53 (56) 0.077
Stay in surgical service 40 (53) 43 (45) 0.001
Stay in burn unit 22 (29) 4 (4) <0.001
Transfer to ICU from another unit 19 (25) 9 (10) 0.034
Surgery 28 (37) 48 (51) 0.086
Hospital stay until infection   22.01±16.6 14.06±12.7 <0.001
(days)
Mechanical ventilation 24 (32) 18 (19) 0.05
Total parenteral nutrition 23 (31) 18 (19) 0.076
Enteral nutrition 11 (15) 12 (13) 0.694
Unconsciousness 20 (27) 16 (17) 0.120
Central venous catheter 21 (28) 19 (20) 0.237
Peripheral venous catheter 74 (99) 88 (93) 0.065
Tracheostomy 12 (16) 5 (5) 0.021
Endotracheal tube 17 (23) 14 (15) 0.170
Urinary catheter 41 (55) 43 (45) 0.223
Arterial line 23 (31) 14 (15) 0.012
Surgical drain 16 (21) 13 (14) 0.188
Hemodialysis catheter 4 (5) 7 (7) 0.417
APACHE II score (mean) 17.4±6.8 13.3±6.7 0.026
APACHE II score ≥20 12 (39) 4 (15) 0.042
Previous use of amikacin 11 (15) 4 (5) 0.025
Previous use of vancomycin 24 (33) 9 (10) 0.001
Previous use of piperacillin- 16 (22) 6 (7) 0.007
tazobactam
Previous use of imipenem 19 (26) 7 (8) 0.002
Previous use of combination of  8 (11) 1 (1) 0.012
vancomycin and imipenem
Previous use of ciprofloxacin 5 (7) 11 (13) 0.215
Previous use of ampicillin- 11 (15) 14 (16) 0.834
sulbactam
Previous use of cefoperazone- 6 (8) 4 (5) 0.282
sulbactam
Previous use of cefepime 3 (4) 2 (2) 0.521
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2.187-18.875, p=0.001), and imipenem (OR, 3.580; 95%
CI, 1.252-10.245, p=0.017) treatment within the 14 days
before isolation of IRPA were independently associated with
imipenem resistance (Table 3).
Previous use of amikacin, vancomycin, imipenem and
piperacillin-tazobactam was present in 15%, 33%, 26%,
and 22% of the patients with IRPA and 5%, 10%, 8%, and
7% of the patients with ISPA infection, respectively.
The resistance rates of IRPA isolates to the other antibi-
otics were frequently higher than those ISPA isolates (Table
4). Eleven (6.4%) of the P. aeruginosa isolates were resistant
to all tested antibiotics. 
Four patients whose initial isolates were imipenem-sus-
ceptible were subsequently recovered to be imipenem-resis-
tant during the same hospital stay. All of these patients had
received imipenem between the isolations.
There was no outbreak due to P. aeruginosa during the study
period. 
DISCUSSION
P. aeruginosa is one of the most common hospital-acquired
gram-negative pathogens (10, 11). Because of increase of
imipenem resistance, studies were done to determine the
risk factors for IRPA infections (6, 8, 12, 13). Generally,
these studies were retrospective and some of them included
a limited number of patients (12, 13). Besides, they might
have some limitations in the exclusion of colonized patients.
In a recent study, a comparative approach of two case-control
studies with distinct control groups was used (6). In this
study, we have done a prospective case-control study with
detailed evaluation of many risk factors including physical
examination of cases by an infectious disease specialist.
In this study, the frequency of IRPA infections was 1.35
cases/1,000 hospital admissions and among the P. aeruginosa
infections imipenem resistance was observed as 44.1%.
Although there was no similar published studies to compare
the incidence of patients with IRPA, the overall incidence
of IRPA infection/colonisation in Turkey was reported approx-
imately 19% in 1997 and 13% in 1998 (14). This two to
three-fold increase reflecting the striking rise in imipenem
resistance in our country correlates to other reports notifying
this issue (4-7, 15). In ICUs approximately two-fold increase
in imipenem resistance of the P. aeruginosa isolates was observed
(53.4%), when compared to another study (21% in 1997,
27% in 1998) from our country (14). Some studies found
ICU exposure as a risk factor for imipenem resistance in P.
aeruginosa (12, 16-18). However, supporting the findings of
Troillet et al. and Zavascki et al., ICU stay was not predic-
tive of resistance of P. aeruginosa to imipenem in our study
(6, 13). Sex and age were not risk factors for IRPA infec-
tions in our study, which was compatible with other studies
(6, 8, 13).
Multivariate analysis showed that, a longer duration of hos-
pital stay until P. aeruginosa isolation (OR, 1.027; 95% CI,
1.002-1.054, p=0.034), arterial catheter administration (OR,
2.508; 95% CI, 1.062-5.920, p=0.036), vancomycin (OR,
2.882; 95% CI, 1.130-7.349, p=0.027), piperacillin-tazobac-
tam (OR, 6.425; 95% CI, 2.187-18.875, p=0.001), and
imipenem (OR, 3.580; 95% CI, 1.252-10.245, p=0.017)
treatment within the 14 days before isolation of IRPA were
independently associated with imipenem resistance.
A longer hospital stay identified as a risk factor in this
study was similar to the other studies (12, 13, 17, 19). It is
a well known risk factor for many antibiotic-resistant microor-
ganisms (16). Antibiotic-susceptible microorganisms in body
flora of the hospitalized patients can be replaced with antibi-
otic resistant strains which are available at hospital environ-
ment over time. Due to flora changes, prolonged hospital
stay is a risk factor in all units and all types of nosocomial
infections (20). 
The risk of IRPA infection was 2.5 times higher for arte-
rial catheter administration in this study. Although this has
not been reported previously, identification of arterial catheter
as a risk factor is not an unexpected finding. As most of the
patients with IRPA infections are critically ill, they are sub-
ject to invasive procedures such as arterial catheter, endotra-
cheal tube, central venous catheter and urinary catheter. 
Antibiotic exposure remains one of the most important
risk factor for the acquisition of IRPA infection (19). In this
study, prior antibiotic use was defined as at least 24 hr of ther-
apy during the 14 days prior to isolation of the P. aeruginosa.
The mean days and range of previous therapy with vanco-
mycin, piperacillin-tazobactam, and imipenem were 10.6
(2-22), 9.3 (2-34), and 11.7 (2-28), respectively. According
to our results the previous use of vancomycin, piperacillin-
tazobactam and imipenem were associated with imipenem
resistance. The risk for imipenem resistance was 6.4 times
higher in previous use of piperacillin-tazobactam, 3.5 times
higher for imipenem and 2.8 times higher for vancomycin.
IRPA (n=75)
n (%)
ISPA (n=95)
n (%) 
p
value
Table 4. Antimicrobial resistance rates of imipenem-sensitive
P. aeruginosa (ISPA) and imipenem-resistant P. aeruginosa
(IRPA) isolates to the other antibiotics
Amikacin 52 (70) 18 (19) 0.0001
Gentamicin 64 (85) 40 (42) 0.0001
Netilmicin 64 (85) 33 (35) 0.0001
Tobramicin 65 (87) 36 (38) 0.0001
Aztreonam 65 (87) 63 (66) 0.008
Cefepime 61 (81) 48 (51) 0.0001
Ceftazidime 45 (60) 56 (59) 0.977
Ciprofloxacin 58 (77) 30 (32) 0.0001
Pefloxacin 63 (84) 31 (33) 0.0001
Piperacillin/tazobactam 46 (61) 29 (31) 0.0001
Ticarcillin/clavulanate 63 (84) 42 (44) 0.0001
Trimethoprim/sulphametoxazole 72 (96) 71 (75) -986 P. Onguru, A. Erbay, H. Bodur, et al.
The high risk of previous use of piperacillin-tazobactam for
imipenem resistance was especially striking in our study.
Except a recent study (17), imipenem has been identified
as a major risk factor for IRPA in previous studies (6, 12,
16). Using control patients with ISPA, Troillet et al. identi-
fied imipenem as the only antibiotic associated with IRPA
and reported the highest OR (OR, 23.2; 95% CI, 4.1-132.7)
(13). With a similar control group, Zavascki et al. also report-
ed carbapenem as the only antibiotic associated with the risk
of IRPA (OR, 12.82; 95% CI, 3.99-41.23) (6). The lower
OR for imipenem was found in our study is similar to the
study of Harris et al. (OR, 4.96; 95% CI, 2.88-8.57) (12).
Despite the strength of this association, imipenem exposure
can explain only 26% of the imipenem resistance in initial
isolates. In contrast, among the patients who had initially
susceptible and subsequent resistant isolates recovered, all
were exposed to imipenem. 
The association between previous piperacillin-tazobactam
use and IRPA in this study has been only identified previ-
ously by Harris et al. (12). We noted a higher OR 6.425
(95% CI, 2.187-18.875, p=0.001) for piperacillin-tazobac-
tam than that found in the study of Harris et al. (OR, 2.19;
95% CI, 1.42-4.03). The treatment with other β -lactam
antibiotics have been thought to predispose for imipenem
resistance by selecting strains with stably depressed β -lacta-
mase production, which could then be more likely to lose
their porin OprD2 (21).
Our study showed vancomycin as a significant risk factor.
Harris et al. also reported vancomycin as a risk factor for
IRPA isolation (12). On the other hand, Zavascki et al. report-
ed that the combination of carbapenem and vancomycin
significantly increased the risk of imipenem resistance. How-
ever, they did not confirm this finding in their second study
model with the control group of ISPA. It has been hypothe-
sized that vancomycin may select for Pseudomonas species by
destroying competing gram-positive bacteria that are part
of enteric or bronchial flora (6). In this study, previous use of
combined treatment of vancomycin plus imipenem was not
independently associated with imipenem resistance.
The isolates of IRPA were often multidrug resistant caus-
ing a difficulty in the treatment and control of these infections.
Eleven (6.4%) of the P. aeruginosa isolates were resistant to
all tested antibiotics in this study. Antimicrobial resistance
rates of IRPA were high (≥70%) for amikacin, gentamicin,
netilmicin, tobramicin, aztreonam, cefepime, ciprofloxacin,
pefloxacin, ticarcillin/clavulanate, and trimethoprim/sul-
phamethoxazole. Imipenem resistance was frequently associated
with resistance to other common antipseudomonal agents
(Table 4). The lack of association between imipenem and cef-
tazidime resistance can be explained by rare prescription of
ceftazidime in our hospital.
Solid organ transplantation, mechanical ventilation and
renal failure have been identified as risk factors in different
studies (6, 13, 18, 19). In our study, we did not identify them
as risk factors for IRPA. Besides, we could not confirm the
results of the National Nosocomial Infections Surveillance
system study that found that respiratory tract culture speci-
mens were predictive of resistance of P. aeruginosa to imipenem. 
Two limitations were present in this study. Our study was
not based on molecular epidemiologic investigation. The
other was the limited number of IRPA cases in this study,
although 75 cases of IRPA were investigated.
In conclusion, our results suggest that the nosocomial
occurrence of IRPA infections is strongly related to longer
duration of hospital stay and arterial catheter administra-
tion. Prior uses of imipenem, vancomycin and piperacillin-
tazobactam were independent risk factors for nosocomial
IRPA infections. Considering the high rate of IR in P. aerugi-
nosa infections in this study, we should carefully reconsider
the whole prevention and control measures.
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